Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
|Articles|March 2, 2023
- Pharmaceutical Technology, March 2023
- Volume 47
- Issue 3
- Pages: 12
CHO-Based Assay Kit
Charles River’s HCP-ELISA kit is designed to increase the efficiency and efficacy of HCP assay development.
Charles River Laboratories’ enzyme-linked immunosorbent assay (ELISA) kit is designed for the detection and quantitation of residual host cell proteins (HCP) in Chinese hamster ovary (CHO)-based biotherapeutics. Building on the company’s HCP-GAPex service, the HCP–ELISA kit is designed to increase the efficiency and efficacy of HCP assay development.
The HCP–ELISA kit has a 96-well assay plate and has a time-to-result of approximately three hours. It leverages avian immunoglobulin Y antibodies as the primary detection technology, which are derived from specific-pathogen-free chicken eggs developed exclusively by AVS Bio.
Articles in this issue
over 3 years ago
Harnessing Technology to Ensure Drug Safetyover 3 years ago
Excipients Impact Stability in mRNA-LNP Formulationsover 3 years ago
Influencing Change in Drug Deliveryover 3 years ago
Frontrunner in Microbiome Therapeuticsover 3 years ago
Implementing Process Analytical Technologyover 3 years ago
Taking Steps Toward Supply Chain Continuityover 3 years ago
Keeping Europe’s Medicines StockedRelated to this article
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
Bettina Brierley, chief commercial officer at Celtic Renewables, discusses commercialization of biosolvents for pharmaceutical manufacturing.
Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
Onshoring pharmaceutical manufacturing can be made more practical by collaborating with CDMOs that have gray space, supported by strong relationships with used equipment dealers and OEMs.
USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains the benefits and challenges of the company’s just-in-time manufacturing solution.
Trending on Pharmaceutical Technology
1
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
2
The Impact of Excipients on Continuous Manufacturing and the Risk of Nitrites
3
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
4
Drapeau’s AI Deep Dive: Qualify the Reviewer Before the AI Goes Live
5